Company Filing History:
Years Active: 2023
Title: The Innovative Contributions of James Hilger
Introduction
James Hilger is a notable inventor based in Zürich, Switzerland. He has made significant contributions to the field of medical science, particularly in the treatment of lymphomas. His work focuses on innovative methods that enhance patient care and treatment outcomes.
Latest Patents
James Hilger holds a patent for a method titled "Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors." This patent discloses a method for the prevention, delay of progression, or treatment of indolent or aggressive B-cell lymphomas in individuals. The method involves administering a BTK inhibitor, specifically (S)-7-(1-actyloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an anti-PD-1 antibody. The combination has shown a manageable toxicity profile in patients suffering from these types of lymphomas.
Career Highlights
James Hilger is currently associated with Beigene Switzerland GmbH, where he continues to work on groundbreaking research and development in oncology. His expertise and innovative approach have positioned him as a key figure in the medical research community.
Collaborations
James has collaborated with esteemed colleagues such as Xiaoping Zhang and Shibao Feng. Their combined efforts contribute to advancing the understanding and treatment of lymphomas.
Conclusion
James Hilger's innovative work in the treatment of B-cell lymphomas exemplifies the impact of dedicated research in the medical field. His contributions are paving the way for improved therapies and better patient outcomes.